Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
eXp World (EXPI)
Consensus Price Target: $11 (84.7% implied return)
Founded in 2009, eXp World (NASDAQ: EXPI) is a real estate company known for its virtual, cloud-based approach to real estate brokerage.
Why Do We Think EXPI Will Underperform?
- Lackluster 5.7% annual revenue growth over the last two years indicates the company is losing ground to competitors
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 3.1% for the last two years
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
eXp World’s stock price of $5.95 implies a valuation ratio of 22x forward P/E. Dive into our free research report to see why there are better opportunities than EXPI.
Genco (GNK)
Consensus Price Target: $27.63 (30.2% implied return)
Headquartered in NYC, Genco (NYSE: GNK) is a shipping company that transports dry bulk cargo along worldwide maritime routes.
Why Do We Pass on GNK?
- Performance surrounding its owned vessels has lagged its peers
- Performance over the past two years shows each sale was less profitable as its earnings per share dropped by 43.5% annually, worse than its revenue
- Free cash flow margin shrank by 55.6 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
At $21.23 per share, Genco trades at 17.4x forward P/E. Check out our free in-depth research report to learn more about why GNK doesn’t pass our bar.
One Stock to Watch:
Astrana Health (ASTH)
Consensus Price Target: $36 (46.5% implied return)
Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.
Why Does ASTH Stand Out?
- Impressive 51.5% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Revenue outlook for the upcoming 12 months is outstanding and shows it’s on track to gain market share
- Earnings growth has trumped its peers over the last five years as its EPS has compounded at 15.9% annually
Astrana Health is trading at $24.57 per share, or 9x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
